FIELD: immunology.
SUBSTANCE: present invention relates to immunology. Disclosed are antibodies targeting B-Cell maturation antigen (BCMA) or their fragment antigen bindings, compositions for treating malignant tumors, an immunoconjugate, a bispecific molecule. Disclosed are also a nucleic acid molecule, an expression vector, a host cell, BCMA detection method. Besides, disclosed are method for treating a tumor, use of anti-BCMA antibody, a set for treating a tumor.
EFFECT: present invention may be further implemented in therapy of tumors relating to B-Cell maturation antigen (BCMA) expression.
32 cl, 20 tbl, 10 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B CELLS, AND THEIR APPLICATION | 2015 |
|
RU2761632C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| ANTIBODY MOLECULES AGAINST APRIL AND APPLICATIONS THEREOF | 2016 |
|
RU2793755C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-NK-CELLS | 2020 |
|
RU2795443C2 |
| ANTIBODY PURIFICATION | 2019 |
|
RU2812161C2 |
